Clinical Application of OCT in Stent Evaluation

Similar documents
malapposition assessed by OCT

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.

Bifurcation Stenting: IVUS and OCT Information

Drug eluting stents (DES) have decreased

Optical Coherence Tomography for Intracoronary Imaging

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

Usefulness of OCT during coronary intervention

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

Resolute Integrity. Independent Conformability Assessment

Cover Page. Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence tomography Issue Date:

Catch-up Phenomenon: Insights from Pathology

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

DES in Diabetic Patients

OCT Findings: Lesson from Stable vs Unstable Plaques

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study

Second Generation Drug Eluting Stents: From Inhibition to Healing

Vessel healings after stenting with different polymers in STEMI patients

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

SMJ Singapore Medical Journal

Evaluation of stent placement and outcomes with optical coherence tomography

Next Generation Drug- eluting Stent : Will It Solve the Problem?

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

DES In-stent Restenosis

Drug eluting stents From revolution to evolution. Current limitations

Insights in Thrombosis and In-Stent Restenosis

Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

eluting Stents The SPIRIT Trials

Lessons for technique and stent choice

Biodegradable Stents An update and work-in

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition

Bench Insights into Bifurcation Stenting in the DES Era: An Update

Carotid Intravascular Imaging Technique and Indication

From a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.

PCI with Polymer-free Stent

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

Left main coronary artery (LMCA): The proximal segment

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

PCI for Long Coronary Lesion

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Non stent based intracoronary drug delivery

PCI for In-Stent Restenosis. CardioVascular Research Foundation

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

BIOFREEDOM: Polymer free Biolimus A9 eluting

INTRODUCTION. Catheterization and Cardiovascular Interventions 82:E871 E878 (2013)

Goal: Optimal Stent Deployment

ORIGINAL ARTICLE. Methods. Imaging

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents

European Heart Journal - Cardiovascular Imaging Advance Access published January 4, 2013

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

The Role of Optical Coherence Tomography in Coronary Intervention

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Index. B Bare metal stents (BMS) vs. DES, 172 OCT findings, 170, 172

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

Intravascular Ultrasound in the Drug-Eluting Stent Era

What Stent to Use? JASVINDAR SINGH MD, FACC

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Coronary Stent Choice in Patients With Diabetes Mellitus

Boston Scientific Corporation Drug-Eluting Stent Program

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment

DES και θρόμβωση. Dimitrios Alexopoulos

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent

Biosensors Lunch Symposium

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up

Stent thrombosis: How to manage it Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King s College Hospital, London, UK.

Shedding light on stent thrombosis

BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program

The 3 top Messages from technique Specific problems Solving

Pathology of Cardiovascular Interventions. Body and Disease 2011

For Personal Use. Copyright HMP 2013

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

Can IVUS Define Plaque Features that Impact Patient Care?

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents

Drug eluting balloons in CAD

FOR IMMEDIATE RELEASE

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

LCX. President / Director of Cardiology / New Tokyo Hospital

Optical Coherence Tomography

World Congress of Cardiology PARIS: August 27-31, ESC Andreas Gruentzig lecture on Interventional Cardiology

as a Mechanism of Stent Failure

DESolve NX Trial Clinical and Imaging Results

Transcription:

Imaging & Physiology Summit 2010 in Soul #1. Basics of Image Interpretation: IVUS/VH/OCT Clinical Application of OCT in Stent Evaluation Mitsuyasu Terashima, MD, PhD, FACC

Stent implantation

Stent Apposition

Incomplete apposition BX 3.5*33mm After stenting of the mid-lad with inflation pressure at 10 atm Incomplete apposition

OCT Image of Implanted stent Just after Deployment Complete stent apposition (CSA) Apposition of stent strut to the vessel wall is evaluated by measuring the distance between the strut surface and adjacent vessel surface. Stent Strut thickness Near infrared light used of strut in OCT cannot penetrate the Dorsal metallic stent strut, so stent Shadowing struts are visualized as linear structures with strong surface reflection and typical dorsal shadowing. Incomplete stent apposition (ISA) Stent Strut > thickness of strut

Jornal of Invasive Cardiology 2009;21:602 605

A B C D E Fig. 3: Cross sectional optical coherence tomography images of individual stents implanted in the phantom model A: Bx Velocity stent, B: Cypher stent, C: Express2 stent, D: Driver stent, E: Vision stent

Frequency (%) 30 20 10 A Manufacturer s nominal thickness Frequency (%) 40 30 20 10 B Manufacturer s nominal thickness 0 120 130 140 150 160 170 Strut Thickness m 0 130 140 150 160 170 18 Strut Thickness m 0 Frequency (%) 40 30 20 10 C Manufacturer s nominal thickness Frequency (%) 30 20 10 D Manufacturer s nominal thickness Frequency (%) 30 20 10 E Manufacturer s nominal thickness 0 10 0 110 120 130 140 150 160 Strut Thickness m 0 70 80 90 100 110 Strut Thickness m 0 60 70 80 90 100 110 Strut Thickness m Fig. 4: Histograms of measurements of individual stents A: Bx Velocity stent, B: Cypher stent, C: Express2 stent, D: Driver stent, E: Vision stent Jornal of Invasive Cardiology 2009;21:602 605

Type of stent Bx- Velocity Table 1. Measured and Manufacturers nominal strut thickness Number Measured Thickness (mm) Table 1 Measured and Manufacturers nominal strut thickness 95% CI (mm) Manufacturer s nominal thickness (mm) 42 145 13 141 to 149 140 (0.0055 inch) Cypher 42 152 11 149 to 155 160 (0.0055 inch + polymer) Express 50 129 12 126 to 132 132 (0.0052 inch) Driver 60 88 10 86 to 91 91 (0.0036 inch) Vision 45 84 14 79 to 88 81 (0.0032 inch) Difference (mm) +5 13-8 11-3 12-3 10 Measured stent strut thickness in m, expressed as mean SD as compared to manufacturers nominal strut thickness; CI: confidence interval 3 14 Jornal of Invasive Cardiology 2009;21:602 605

How to measure? 120µm 140µm 160µm

120µm 140µm 160µm

Fates of Incomplete Apposition Baseline Incomplete Apposition Healed/Resolved Incomplete Apposition Preserved Incomplete Apposition

They concluded that; In Should patients we treat with all SESs. of the ISA incompletely can fail to heal and apposed even struts? complete apposition can be associated Although in-stent with no thrombus neointimal is common hyperplasia. Incomplete findings in DES, stent late apposition stent thrombosis without is a neointimal rare event. hyperplasia was significantly associated Futhermore, with there the is presence no significant of clinical OCT-detected data for relationships thrombus between at follow-up. baseline and ISA may and late constitute stent thrombosis. a potent substrate for late stent Then, thrombosis there any acceptable indication for treatment of ISA?

Flap / Dissection IVUS OCT

Chronic Vascular Responses to Coronary Stenting by Optical Coherence Tomography

Neointimal Coverage of Stent struts

IVUS and OCT image of SES at 3-month follow-up OCT provides detailed visualization of the individual stent struts and a thin neointimal layer over DES struts that IVUS can not detect.

Classification of Neointimal Coverage ~ Morphology ~

Intimal Stent Strut Coverage Type 1 & 2

Intimal Stent Strut Coverage Type 3

Intimal Stent Strut Coverage Type 4

Definition of Neointimal Coverage of Struts Uncovered Struts Covered Struts Type 1 Stent Strut Stent Strut Type 3 NIT Type 2 Dorsal Shadowing Type 4 NIT Ito t, et al, 2006 ACC

Intimal Coverage of unapposed Stent Strut

Classification of Neointimal Coverage of Strut by Kobe University (1) Well apposed with neointima (2) Well apposed without neointima (3) Malapposed with neointima (4) Malapposed without neointima (5) Side branch orifice with neointima (6) Side branch orifice without neointima Malapposition: Incomplete Stent Apposition (ISA) Fig. Images of stent in chronic phase OCT

Is the scientific consensus of OCT findings obtained?

How about this? No1

How about this? No2

Comparison of Neointimal Growth between Paclitaxel-Eluting Stent, Sirolimus-Eluting Stent, and Bare-Metal Stent

Frequencies of Covered Strut / Stents P < 0.01 ( % ) 100 P < 0.01 90 80 70 60 50 98.8 2.1% 96.2 3.8% 86.7 11.7% BMS 3M n = 10 PES 3M n = 13 SES 3M n = 13

CASE: BMS, SES and PES ~ 4-month f/u ~ Distal

CASE: BMS, SES and PES BMS ~ 4-month f/u ~ Cypher Taxus

26 head-to-head (n>35,000 ) TAXUS Stent Thrombosis (%) 1 18 3.0-2.5-3 2.0-1.5-1.0-0.5- Even with inclusion of the outliers 23 14 19 5 10 2 6 11 12 22 21 13 Slope=1.25 n=35,539 20 24 0-25 I I I I I I I 0 0.5 1.0 1.5 2.0 2.5 3.0 CYPHER Stent Thrombosis (%) 16 26 8 15 9 4 Slope=0.79 TAXUS ST = 1.02 Cypher ST 95% CI (0.79, 1.25) R 2 = 0.76 7 Slope=1.02 17 Slope=1.00 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 I-DIABETES I-SMART I-DESIRE TAXI DEScover S.T.E.N.T. SIRTAX MILAN C & T Reward CORPAL REALITY TC-WYRE REAL LONG DES II SORT OUT II BASKET Cervinka Di Lorenzo Han YL Petronio PROSIT Zhang T-SEARCH/RESEARCH DIABETES I, II RESEARCH Long TAXUS Meta / Cypher Meta n=250 n=360 n=200 n=202 n=6,509 n=10,159 n=1,012 n=529 n=2,769 n=652 n=1,353 n=1,558 n=1,676 n=500 n=2,098 n=545 n=70 n=180 n=416 n=100 n=308 n=449 n=1,084 n=160 n=122 n=2,278 Trials excluded in analysis: SOLACI (ST not reported) ARRIVE I / II, e-cypher, TAXUS V and SISR ( differences in protocol definitions).

Characteristics of Neointima ~ intensity, pattern ~

Usual Neoitima of BMS

Common findings in 1 st generation DES SES SES

Heterogeneous neointima of 1 st generation DES Layered Mosaic PES SES SES

59 y.o. male Pre Post Cypher 2.5*23 Stenting 4M fu

Case 2: OCT at 4 months fu

Specimen Retrieved by DCA This case will be presented tommorow!

Anomalous pattern of Neointima Peri-stent staining Peri-strut ulcer like apperance / Peri-strut halo

Neointima following stent implantation have various patterns of morphology or characteristics (intensity, etc). Question? Which patterns are safe (protective for stent thrombosis)? Which patterns are dangerous? Which patterns are within the acceptable range?

Summary OCT provides various information and new aspects of implanted stents. Unfortunately, consensus of definition of OCT findings has not been obtained. Therefore, interpretation of the study using OCT requires attention. Lager population study should be required to clarify the relationships between OCT findings and clinical outcomes after achieving consensus standard of OCT findings.